Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $0.25.

  • Kiniksa Pharmaceuticals International's EPS (Basic) rose 23888.89% to $0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.49, marking a year-over-year increase of 47692.31%. This contributed to the annual value of -$0.6 for FY2024, which is 40236.97% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its EPS (Basic) stood at $0.25 for Q3 2025, which was up 23888.89% from $0.24 recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's EPS (Basic)'s 5-year high stood at $3.23 during Q3 2022, with a 5-year trough of -$0.72 in Q1 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median EPS (Basic) value was -$0.18 (recorded in 2023), while the average stood at $0.09.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 83409.09% in 2022, then tumbled by 13456.66% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's EPS (Basic) stood at -$0.52 in 2021, then skyrocketed by 345.37% to $1.28 in 2022, then crashed by 71.79% to $0.36 in 2023, then tumbled by 134.57% to -$0.12 in 2024, then soared by 300.9% to $0.25 in 2025.
  • Its EPS (Basic) stands at $0.25 for Q3 2025, versus $0.24 for Q2 2025 and $0.12 for Q1 2025.